Browse AURKB

Summary
SymbolAURKB
Nameaurora kinase B
Aliases Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Chromosome. Chromosome, centromere. Cytoplasm, cytoskeleton, spindle. Midbody. Note=Localizes on chromosome arms and inner centromeres from prophase through metaphase and then transferring to the spindle midzone and midbody from anaphase through cytokinesis. Colocalized with gamma tubulin in the midbody. Proper localization of the active, Thr-232-phosphorylated form during metaphase may be dependent upon interaction with SPDYC. Colocalized with SIRT2 during cytokinesis with the midbody. Localization (and probably targeting of the CPC) to the inner centromere occurs predominantly in regions with overlapping mitosis-specific histone phosphorylations H3pT3 and H2ApT12.
Domain PF00069 Protein kinase domain
Function

Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Involved in the bipolar attachment of spindle microtubules to kinetochores and is a key regulator for the onset of cytokinesis during mitosis. Required for central/midzone spindle assembly and cleavage furrow formation. Key component of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage: phosphorylates CHMP4C, leading to retain abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis (PubMed:22422861, PubMed:24814515). AURKB phosphorylates the CPC complex subunits BIRC5/survivin, CDCA8/borealin and INCENP. Phosphorylation of INCENP leads to increased AURKB activity. Other known AURKB substrates involved in centromeric functions and mitosis are CENPA, DES/desmin, GPAF, KIF2C, NSUN2, RACGAP1, SEPT1, VIM/vimentin, HASPIN, and histone H3. A positive feedback loop involving HASPIN and AURKB contributes to localization of CPC to centromeres. Phosphorylation of VIM controls vimentin filament segregation in cytokinetic process, whereas histone H3 is phosphorylated at 'Ser-10' and 'Ser-28' during mitosis (H3S10ph and H3S28ph, respectively). A positive feedback between HASPIN and AURKB contributes to CPC localization. AURKB is also required for kinetochore localization of BUB1 and SGO1. Phosphorylation of p53/TP53 negatively regulates its transcriptional activity. Key regulator of active promoters in resting B- and T-lymphocytes: acts by mediating phosphorylation of H3S28ph at active promoters in resting B-cells, inhibiting RNF2/RING1B-mediated ubiquitination of histone H2A and enhancing binding and activity of the USP16 deubiquitinase at transcribed genes.

> Gene Ontology
 
Biological Process GO:0000022 mitotic spindle elongation
GO:0000070 mitotic sister chromatid segregation
GO:0000075 cell cycle checkpoint
GO:0000226 microtubule cytoskeleton organization
GO:0000723 telomere maintenance
GO:0000819 sister chromatid segregation
GO:0000910 cytokinesis
GO:0001783 B cell apoptotic process
GO:0002902 regulation of B cell apoptotic process
GO:0002903 negative regulation of B cell apoptotic process
GO:0006278 RNA-dependent DNA biosynthetic process
GO:0007004 telomere maintenance via telomerase
GO:0007051 spindle organization
GO:0007052 mitotic spindle organization
GO:0007059 chromosome segregation
GO:0007062 sister chromatid cohesion
GO:0007067 mitotic nuclear division
GO:0007568 aging
GO:0008608 attachment of spindle microtubules to kinetochore
GO:0009314 response to radiation
GO:0009411 response to UV
GO:0009416 response to light stimulus
GO:0009838 abscission
GO:0010324 membrane invagination
GO:0010498 proteasomal protein catabolic process
GO:0010833 telomere maintenance via telomere lengthening
GO:0010948 negative regulation of cell cycle process
GO:0016233 telomere capping
GO:0016570 histone modification
GO:0016572 histone phosphorylation
GO:0016925 protein sumoylation
GO:0018105 peptidyl-serine phosphorylation
GO:0018205 peptidyl-lysine modification
GO:0018209 peptidyl-serine modification
GO:0031145 anaphase-promoting complex-dependent catabolic process
GO:0031577 spindle checkpoint
GO:0032091 negative regulation of protein binding
GO:0032200 telomere organization
GO:0032204 regulation of telomere maintenance
GO:0032206 positive regulation of telomere maintenance
GO:0032210 regulation of telomere maintenance via telomerase
GO:0032212 positive regulation of telomere maintenance via telomerase
GO:0032465 regulation of cytokinesis
GO:0032466 negative regulation of cytokinesis
GO:0032467 positive regulation of cytokinesis
GO:0032506 cytokinetic process
GO:0032844 regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0033044 regulation of chromosome organization
GO:0034501 protein localization to kinetochore
GO:0034502 protein localization to chromosome
GO:0034644 cellular response to UV
GO:0035404 histone-serine phosphorylation
GO:0036089 cleavage furrow formation
GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043393 regulation of protein binding
GO:0043988 histone H3-S28 phosphorylation
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0046777 protein autophosphorylation
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051098 regulation of binding
GO:0051100 negative regulation of binding
GO:0051225 spindle assembly
GO:0051231 spindle elongation
GO:0051255 spindle midzone assembly
GO:0051256 mitotic spindle midzone assembly
GO:0051302 regulation of cell division
GO:0051781 positive regulation of cell division
GO:0051782 negative regulation of cell division
GO:0051972 regulation of telomerase activity
GO:0051973 positive regulation of telomerase activity
GO:0051983 regulation of chromosome segregation
GO:0060249 anatomical structure homeostasis
GO:0061640 cytoskeleton-dependent cytokinesis
GO:0070227 lymphocyte apoptotic process
GO:0070228 regulation of lymphocyte apoptotic process
GO:0070229 negative regulation of lymphocyte apoptotic process
GO:0071214 cellular response to abiotic stimulus
GO:0071459 protein localization to chromosome, centromeric region
GO:0071478 cellular response to radiation
GO:0071482 cellular response to light stimulus
GO:0071887 leukocyte apoptotic process
GO:0071897 DNA biosynthetic process
GO:0072331 signal transduction by p53 class mediator
GO:0090068 positive regulation of cell cycle process
GO:0090307 mitotic spindle assembly
GO:0098813 nuclear chromosome segregation
GO:0099024 plasma membrane invagination
GO:1901796 regulation of signal transduction by p53 class mediator
GO:1902850 microtubule cytoskeleton organization involved in mitosis
GO:1904353 regulation of telomere capping
GO:1904355 positive regulation of telomere capping
GO:1904356 regulation of telomere maintenance via telomere lengthening
GO:1904358 positive regulation of telomere maintenance via telomere lengthening
GO:2000106 regulation of leukocyte apoptotic process
GO:2000107 negative regulation of leukocyte apoptotic process
GO:2000278 regulation of DNA biosynthetic process
GO:2000573 positive regulation of DNA biosynthetic process
GO:2001252 positive regulation of chromosome organization
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004712 protein serine/threonine/tyrosine kinase activity
GO:0035173 histone kinase activity
GO:0035174 histone serine kinase activity
Cellular Component GO:0000775 chromosome, centromeric region
GO:0000776 kinetochore
GO:0000779 condensed chromosome, centromeric region
GO:0000780 condensed nuclear chromosome, centromeric region
GO:0000793 condensed chromosome
GO:0000794 condensed nuclear chromosome
GO:0000922 spindle pole
GO:0005813 centrosome
GO:0005819 spindle
GO:0005874 microtubule
GO:0005875 microtubule associated complex
GO:0005876 spindle microtubule
GO:0010369 chromocenter
GO:0030496 midbody
GO:0031616 spindle pole centrosome
GO:0032133 chromosome passenger complex
GO:0044454 nuclear chromosome part
GO:0045171 intercellular bridge
GO:0051233 spindle midzone
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-174143: APC/C-mediated degradation of cell cycle proteins
R-HSA-174178: APC/C
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-68886: M Phase
R-HSA-392499: Metabolism of proteins
R-HSA-68882: Mitotic Anaphase
R-HSA-2555396: Mitotic Metaphase and Anaphase
R-HSA-68877: Mitotic Prometaphase
R-HSA-597592: Post-translational protein modification
R-HSA-195258: RHO GTPase Effectors
R-HSA-5663220: RHO GTPases Activate Formins
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation
R-HSA-453276: Regulation of mitotic cell cycle
R-HSA-2500257: Resolution of Sister Chromatid Cohesion
R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins
R-HSA-2990846: SUMOylation
R-HSA-4615885: SUMOylation of DNA replication proteins
R-HSA-2467813: Separation of Sister Chromatids
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolAURKB
Nameaurora kinase B
Aliases Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AURKB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolAURKB
Nameaurora kinase B
Aliases Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AURKB in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.61 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolAURKB
Nameaurora kinase B
Aliases Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AURKB in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5280.227
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7640.678
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3690.815
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8680.127
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.1650.365
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5060.786
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.230.553
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5330.646
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2130.853
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.6690.516
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.9730.518
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5519.06e-05
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AURKB in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAURKB
Nameaurora kinase B
Aliases Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AURKB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAURKB
Nameaurora kinase B
Aliases Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AURKB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AURKB.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAURKB
Nameaurora kinase B
Aliases Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AURKB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAURKB
Nameaurora kinase B
Aliases Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AURKB expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAURKB
Nameaurora kinase B
Aliases Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AURKB and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAURKB
Nameaurora kinase B
Aliases Aik2; IPL1; AurB; ARK2; STK5; PPP1R48; aurora-B; aurora-1; protein phosphatase 1, regulatory subunit 48; STK ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AURKB collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting AURKB.
ID Name Drug Type Targets #Targets
DB04703HESPERIDINSmall MoleculeAURKB1
DB05169AT9283Small MoleculeAURKA, AURKB2
DB06486EnzastaurinSmall MoleculeAKT1, AURKA, AURKB, CDK15, CHEK1, CHEK2, PIK3R1, PRKCB8
DB07340N~6~-cyclohexyl-N~2~-(4-morpholin-4-ylphenyl)-9H-purine-2,6-diamineSmall MoleculeAURKB, INCENP2